首页> 外文期刊>Journal of pediatric orthopaedics >Botulinum toxin type A injection in alleviating postoperative pain and improving quality of life in lower extremity limb lengthening and deformity correction: a pilot study.
【24h】

Botulinum toxin type A injection in alleviating postoperative pain and improving quality of life in lower extremity limb lengthening and deformity correction: a pilot study.

机译:A型肉毒毒素注射液可减轻下肢肢体延长和畸形矫正的术后疼痛并改善生活质量:一项初步研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The Ilizarov technique is commonly used for lengthening and deformity corrections of the lower limbs in children. Postoperative pain can be significant, affecting quality of life and functional mobility, and often requiring prolonged medication use. Several studies have investigated the antinociceptive actions of botulinum toxin type A (BtX-A), yet evidence for its use in this population is limited. The objectives were to (1) establish the feasibility of a randomized clinical trial in children undergoing limb lengthening or deformity correction and (2) provide preliminary evidence of the beneficial effects of BtX-A in this population. METHODS: Fifty-two patients with a mean age of 13.7 years (range, 5 to 21 y) were randomized to receive either BtX-A or an equivalent volume of sterile saline solution (placebo group), as a single dose during the surgical procedure. Pain, medication use, quality of life, and functional mobility outcomes were assessed in all patients. Adverse events were reported for all patients and classified as minor or major. RESULTS: Differences between groups did not reach statistical significance; however, pain at mid-distraction was found to be slightly lower in the BtX-A group, as compared with the placebo group. Patients in the BtX-A group used less parenteral pain medication in the first 4 days after the surgery, had higher quality of life scores at 3 of the 5 time points assessed, and slightly higher functional mobility scores. All adverse events were expected complications of the lengthening process. No event was considered to be a serious adverse event related to the BtX-A injection itself. There was a trend toward fewer major adverse events in the BtX-A group. CONCLUSIONS: This pilot study established the feasibility of a randomized controlled trial design for in this population. Its findings indicate that BtX-A injections appear to be safe and effective for reducing pain and improving the quality of life and functional mobility of children undergoing lengthening or deformity corrections of the lower limbs. A larger-scale study is currently underway to confirm these preliminary findings.
机译:背景:Ilizarov技术通常用于儿童下肢的延长和畸形矫正。术后疼痛可能很严重,影响生活质量和功能活动能力,通常需要长时间使用药物。几项研究已经调查了A型肉毒杆菌毒素(BtX-A)的抗伤害作用,但在该人群中使用的证据有限。目的是(1)在接受肢体延长或畸形矫正的儿童中建立随机临床试验的可行性,以及(2)提供BtX-A在该人群中的有益作用的初步证据。方法:52例平均年龄为13.7岁(范围为5至21岁)的患者在手术过程中被随机分次接受BtX-A或等体积的无菌盐溶液(安慰剂组) 。在所有患者中评估疼痛,​​药物使用,生活质量和功能活动性结局。据报道所有患者发生不良事件,并分为轻度或重度。结果:两组之间的差异没有统计学意义;但是,与安慰剂组相比,BtX-A组在分散注意力时的疼痛略低。 BtX-A组的患者在手术后的前4天使用较少的肠胃外止痛药,在所评估的5个时间点中的3个时点具有较高的生活质量评分,而功能移动性评分则略高。所有不良事件都是延长过程的预期并发症。没有事件被认为是与BtX-A注射本身有关的严重不良事件。 BtX-A组的主要不良事件有所减少。结论:该初步研究确定了针对该人群的随机对照试验设计的可行性。研究结果表明,BtX-A注射液对于减轻疼痛,改善下肢畸形矫正的儿童的生活质量和功能活动性似乎是安全有效的。目前正在进行一项大规模研究,以确认这些初步发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号